On June 18, 2015, ALJ Dee Lord issued Order No. 6 in Certain Recombinant Factor VIII Products (Inv. No. 337-TA-956).

By way of background, this investigation is based on an April 16, 2015 complaint filed by Baxter International Inc., Baxter Healthcare Corp., and Baxter Healthcare SA (collectively, "Baxter") alleging violation of Section 337 in the importation into the U.S. and sale of certain recombinant factor VIII products that infringe one or more claims of U.S. Patent Nos. 6,100,061; 6,936,441; and 8,084,252.  See our April 17, 2015 and May 19, 2015 posts for more details on the complaint and Notice of Investigation, respectively. 

According to Order No. 6, ALJ Lord granted a joint motion filed by Baxter, Respondents Novo Nordisk A/S and Novo Nordisk Inc., and the Commission Investigative Staff to move the Markman hearing from October 21, 2015 to August 18, 2015 in order to further simplify the investigation